We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

46 hedge funds and large institutions have $154M invested in Orchestra BioMed in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

17% more capital invested

Capital invested by funds: $132M → $154M (+$22.3M)

5% more funds holding

Funds holding: 44 → 46 (+2)

1.48% less ownership

Funds ownership: 60.24% → 58.76% (-1.5%)

67% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 9

Holders
46
Holders Change
+2
Holders Change %
+4.55%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
+$575K
2
TD Asset Management
TD Asset Management
Ontario, Canada
+$528K
3
ECM
ExodusPoint Capital Management
New York
+$340K
4
MF
Magnetar Financial
Illinois
+$76.4K
5
WP
Woodline Partners
California
+$42.2K

Top Sellers

Rank Fund Capital Flow
1
PAMP
Polar Asset Management Partners
Ontario, Canada
-$2.78M
2
PC
Periscope Capital
Ontario, Canada
-$1.03M
3
GPCM
Granite Point Capital Management
Massachusetts
-$593K
4
GL
Governors Lane
New York
-$499K
5
MS
Maven Securities
Jersey
-$379K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$10.9M – – –
Wellington Management Group
2
Wellington Management Group
Massachusetts
$10.9M – – –
BlackRock
3
BlackRock
New York
$10.2M – – –
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$10.2M – – –
CAM
5
Cormorant Asset Management
Massachusetts
$10.2M – – –
PI
6
Putnam Investments
Massachusetts
$9.61M – – –
RCM
7
RA Capital Management
Massachusetts
$8.01M – – –
O
8
OrbiMed
New York
$6.41M – – –
PA
9
Perceptive Advisors
New York
$5.76M – – –
DKCM
10
Davidson Kempner Capital Management
New York
$5.39M -$285K -25,000 -6%
WP
11
Woodline Partners
California
$5.17M +$42.2K +3,699 +0.9%
APM
12
Avidity Partners Management
Texas
$5.12M – – –
BC
13
Boxer Capital
California
$5.12M – – –
EC
14
EcoR1 Capital
California
$5.12M – – –
ACP
15
Acuta Capital Partners
California
$5.03M – – –
LGM
16
Logos Global Management
California
$3.84M – – –
AC
17
Amitell Capital
Singapore
$3.56M +$3.16M +277,669 New
Citadel Advisors
18
Citadel Advisors
Florida
$3.2M – – –
SCM
19
Sio Capital Management
New York
$3.2M – – –
BFM
20
Boothbay Fund Management
New York
$2.96M -$298K -26,113 -10%
AIC
21
AWM Investment Company
New York
$2.56M – – –
AAA
22
Affinity Asset Advisors
New York
$2.56M +$2.28M +200,000 New
KPF
23
K2 Principal Fund
Ontario, Canada
$2.56M +$575K +50,490 +34%
Janus Henderson Group
24
Janus Henderson Group
United Kingdom
$2.18M -$120K -10,495 -6%
GL
25
Governors Lane
New York
$1.68M -$499K -43,750 -25%
1
2

OBIO Hedge Fund Activity: Q4 2020 in Review

46 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q4 2020, worth a combined $154M — up 17% from $132M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new OBIO positions and 4 closed out — a net gain of 2 holders — while 3 added to existing stakes and 9 trimmed.

The largest buyer was K2 Principal Fund, adding an estimated $575K. The largest seller was Polar Asset Management Partners, exiting entirely with an estimated $2.78M sold.

  • 46 institutional investors held Orchestra BioMed (OBIO) as of Q4 2020, up from 44 in Q3 2020.
  • Funds reported $154M of Orchestra BioMed stock for Q4 2020, up 17% quarter-over-quarter.
  • 6 funds opened new Orchestra BioMed positions in Q4 2020 and 4 closed out, a net change of +2 holders.
  • The largest Orchestra BioMed buyer in Q4 2020 was K2 Principal Fund, an estimated $575K added.
  • The largest Orchestra BioMed seller in Q4 2020 was Polar Asset Management Partners, an estimated $2.78M sold.

Based on aggregated 13F filings for Q4 2020.